Early Therapeutic Prediction Based on Tumor Hemodynamic Response Imaging: Clinical Studies in Breast Cancer with Time-Resolved Diffuse Optical Spectroscopy

[1]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[2]  T. Yamane,et al.  In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab , 2016, British Journal of Cancer.

[3]  Akihiko Osaki,et al.  Optical imaging of tumor vascularity associated with proliferation and glucose metabolism in early breast cancer: clinical application of total hemoglobin measurements in the breast , 2013, BMC Cancer.

[4]  Thierry Metens,et al.  Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy , 2016, European Radiology.

[5]  Takashi Kusaka,et al.  Developmental Changes of Optical Properties in Neonates Determined by Near-Infrared Time-Resolved Spectroscopy , 2005, Pediatric Research.

[6]  Paola Taroni,et al.  Breast Tissue Composition and Its Dependence on Demographic Risk Factors for Breast Cancer: Non-Invasive Assessment by Time Domain Diffuse Optical Spectroscopy , 2015, PloS one.

[7]  B. Tromberg,et al.  Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment , 2011, Proceedings of the National Academy of Sciences.

[8]  Akihiko Osaki,et al.  Optical Imaging for Monitoring Tumor Oxygenation Response after Initiation of Single-Agent Bevacizumab followed by Cytotoxic Chemotherapy in Breast Cancer Patients , 2014, PloS one.

[9]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[10]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[11]  A. Buzdar,et al.  Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer , 2006, Cancer.

[12]  M. Oda,et al.  Clinicopathological and prognostic impact of imaging of breast cancer angiogenesis and hypoxia using diffuse optical spectroscopy , 2014, Cancer science.

[13]  H. Tsuda,et al.  Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study , 2011, Breast cancer.

[14]  M. Dowsett,et al.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[16]  Stefan A. Carp,et al.  Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial , 2017, Journal of biomedical optics.

[17]  Yan Zhao,et al.  Optimization of image reconstruction for magnetic resonance imaging–guided near-infrared diffuse optical spectroscopy in breast , 2015, Journal of biomedical optics.

[18]  G Gulsen,et al.  In vivo water state measurements in breast cancer using broadband diffuse optical spectroscopy , 2008, Physics in medicine and biology.

[19]  Bruce J. Tromberg,et al.  Imaging Breast Cancer Chemotherapy Response with Light , 2010, Clinical Cancer Research.

[20]  R. Jain,et al.  Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.

[21]  Quing Zhu,et al.  Ultrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers , 2016, Ultrasonic imaging.

[22]  B. Pogue,et al.  Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. , 2016, Cancer research.

[23]  Noriaki Ohuchi,et al.  Controversies in breast cancer screening for women aged 40-49 years. , 2014, Japanese journal of clinical oncology.

[24]  B. Wilson,et al.  Time resolved reflectance and transmittance for the non-invasive measurement of tissue optical properties. , 1989, Applied optics.

[25]  M. Ellis,et al.  Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool , 2010, British Journal of Cancer.

[26]  Kehu Yang,et al.  MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. , 2018, Breast.

[27]  T. Yamane,et al.  Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis , 2017, Clinical Cancer Research.

[28]  Akiko Shimauchi,et al.  Breast density: the trend in breast cancer screening , 2015, Breast Cancer.

[29]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Tromberg,et al.  Imaging in breast cancer: Diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy , 2005, Breast Cancer Research.

[31]  Monica Morrow,et al.  Locoregional treatment of primary breast cancer , 2010, Cancer.

[32]  Jae Gwan Kim,et al.  Breast tumor hemodynamic response during a breath-hold as a biomarker to predict chemotherapeutic efficacy: preclinical study , 2018, Journal of biomedical optics.

[33]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Quing Zhu,et al.  Assessment of Functional Differences in Malignant and Benign Breast Lesions and Improvement of Diagnostic Accuracy by Using US-guided Diffuse Optical Tomography in Conjunction with Conventional US. , 2016, Radiology.